Project Details
Description
FT522-101: A Phase I Study of FT522 in Combination with Rituximab in Participants with Relapsed/Refractory B-Cell Lymphoma
| Status | Active |
|---|---|
| Effective start/end date | 5/17/23 → 5/31/28 |
Funding
- FATE THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.